|Sponsor / Funder||CSL Behring|
|CI||Dr Michael Lunn|
|UK sites||London Queen Square|
The PATH study was a double-blinded trial of SCIG. This is an extension of the PATH study.
This is an open-label prospective, multi-centre extension study for patients who have participated in the PATH study.
To investigate safety and efficacy of the long-term treatment of CIDP with IgPro20.
Patients may either transition directly from the PATH study to the extension or with an interval.
Patients who received IgG between studies should be enrolled within 1 week after the last administration of IgG.
The treatment duration will be up to 48 weeks, followed by a completion visit (week 49).